What is the catalog number for Naquotinib?

The catalog number for Naquotinib is HY-19729.

What sizes are available for Naquotinib?

Naquotinib is available in the following size(s): 5 mg, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Naquotinib come in?

Naquotinib is available in 5 different pack sizes.

Is Naquotinib in stock?

Naquotinib is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Naquotinib?

Naquotinib is manufactured by QuantiMol.

What is the estimated delivery time for Naquotinib?

Estimated delivery time for Naquotinib is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Naquotinib?

The safety data sheet for Naquotinib is available here: http://file.medchemexpress.com/batch_PDF/HY-19729/Naquotinib-SDS-MedChemExpress.pdf.

Naquotinib

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.

Product Specifications

CAS Number

1448232-80-1

Product Name Alternative

ASP8273

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Naquotinib.html

Purity

98.71

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=NC(CC)=C(O[C@H]2CN(C(C=C)=O)CC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)N

Molecular Formula

C30H42N8O3

Molecular Weight

562.71

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Sakagami H, et al. ASP8273, a novel mutant-selective irreversible EGFR inhibitor, inhibits growth of non-small cell lung cancer (NSCLC) cells with EGFR activating and T790M resistance mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA) : AACR; Cancer Res 2014;74 (19 Suppl) :Abstract nr 1728. doi:10.1158/1538-7445.AM2014-1728|[2]Konagai S, et al. ASP8273 selectively inhibits mutant EGFR signal pathway and induces tumor shrinkage in EGFR mutated tumor models. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA) : AACR; Cancer Res 2015;75 (15 Suppl) :Abstract nr 2586. doi:10.1158/1538-7445.AM2015-2586